Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness

Table 2 Characteristics of study participants

Characteristics	Data (%)
Gender	Female: 19/46 (41.3)
	Male: 27/46 (58.7)
Race	African American: 5/46 (10.9)
	Caucasian: 41/46 (89.1)
Age, yr	Mean: 42.6
	Median: 41.5
	Range: 21-89
Disease type	Ulcerative colitis: 9/46 (19.6)
	Crohn's: 37/46 (80.4)
Use of premedications	17/46 (37.0)
On corticosteroid therapy	1/46 (2.2)
On immunosuppressive therapy	10/46 (21.7)
Dose	5 mg/kg: 25/46 (54.3)
	7.5 mg/kg: 5/46 (10.9)
	10 mg/kg: 16/46 (34.8)
Number of infusions prior to accelerated protocol	Mean: 27.4
	Median: 22
	Range: 4-65
Body mass index	Normal (18.5-25.0): 19/46 (41.3)
	Low (< 18.5): 1/46 (2.2)
	High (> 25.0): 26/46 (56.5)